

Newsletter

December 2008

In this Issue:

- *Has Your Research led to an Invention?*
- *Three State Health Commercialisation Agencies Unite*

HAS YOUR RESEARCH LED TO AN INVENTION?

Has it solved a problem that has been baffling others? Could it become a target for a new drug? Could it be a new drug or a new use for an old drug? A diagnostic test? A new device? If so, it may be patentable!

The Office of Commercialisation looks after IP and research commercialisation for NSCCAHS and is located in the Research Business Unit at Royal North Shore Hospital. It is managed by BioMed North Limited, a not-for-profit research commercialisation agency with over twenty years experience in commercialising research. We are actively looking for research results that may have commercial potential. If your findings are novel, involve an inventive step not obvious to your peers and are useful, please contact us.

Who pays for patents and commercialisation?

The Area pays the required patenting and legal fees and the Office of Commercialisation finds commercial partners to develop your technology.

What do hospital inventors get out of it?

If commercialisation is SUCCESSFUL, net profits are shared among the inventors, their department

and the Area with each getting one third. One inventor received over \$1million dollars when his invention was sold a few years ago. A current inventor, no longer working at Royal North Shore Hospital, has received over \$260,000 to date and we anticipate giving him another \$130,000 this financial year from his share in a Milestone payment.



Professor Carol Pollock with The Hon John Della Bosca MP, NSW Minister for Health, at the opening of Royal North Shore Hospital's Research and Education building during the 25th Scientific Research Meeting of RNSH/UTS/USyd/Kolling Institute of Medical Research on 18 November 2008.

What if I am employed by the University ?

We work with our counterparts at the University on inventions by University staff working on a hospital campus. Agreements are in place for us to handle **joint inventions** with both institutions generally named on a patent but one institution commercialising the invention.

DO YOU THINK YOU HAVE AN INVENTION? OR DO YOU HAVE ANY QUESTIONS ABOUT RESEARCH COMMERCIALISATION - CONTACT THE OFFICE OF COMMERCIALISATION

Ms Sandra See
Email: ssee@officeofcommercialisation.com
Tel: 02 9926 7523

Dr Deborah Kuchler
Email: deborab@deborahkuchler.com
Tel: 0418 726 622

Dr Russell Carrington
Email: russell.carrington@officeofcommercialisation.com
Tel: 0425 251 314

Dr Christine Gockel - New York
Email: christine.gockel@officeofcommercialisation.com
Tel: 0011 1 716 341 7407

The Office of Commercialisation is responsible for all IP owned by NSCCAHS and is also responsible for working with our partnering research organisations, to protect and commercialise any jointly owned IP. Please refer to our website www.officeofcommercialisation.com.

What inventions does NSCCAHS have?

We currently have 17 inventions covering a wide range of areas including

- A Heart Failure therapeutic
- Diagnostic to assess the viability of embryos prior to implantation in IVF
- Therapeutic for Type 1 Diabetes prevention
- Antibody therapeutic for autoimmune and inflammatory diseases
- Combination therapy for Systolic Hypertension in older people.
- Prenatal testing diagnostic
- Peptide therapeutic for inflammatory conditions
- Wound Healing treatment (being commercialised by The University of Sydney)
- Rehabilitation glove device (with University of Wollongong)
- A novel quit smoking approach
- A simplified diagnostic for assessing risk of Obstructive Sleep Apnea
- Simulation Devices for Clinical Training (baby resuscitation; perfusion simulator)
- Novel biomarkers that differentiate aggressiveness of brain tumours (with CSIRO and The University of Sydney)
- Various devices including an IV stand-to-bed coupling device for patient transportation

See <http://www.officeofcommercialisation.com> for Investment Opportunities (inventions) that are currently still available for development from Northern Sydney Central Coast Area Health Service.

Have there been any successful commercialisations?

Yes, certainly!! 7 inventions are currently revenue producing, 1 has been assigned to a start-up company and 7 have been licensed to pharmaceutical, biotech or medical device companies.

Does patenting my IP prevent or delay me from publishing my results?

Not usually. The key thing is NOT to disclose your results until we've filed a Provisional Patent Application. This can take from a few days to a few weeks depending on the complexity of the invention.

What about an abstract, is that a disclosure of my invention?

A disclosure is any type of public disclosure of your invention. It could be in an abstract, a presentation

at a scientific meeting, a poster, a journal article, a thesis and so on. Disclosing your invention publicly means that, when it comes to patenting, it is no longer new! If you have already disclosed your invention please contact us at the Office of Commercialisation as some countries have a 'grace period' to cover inadvertent disclosure.

Three State Health Commercialisation Agencies Unite

In an Australian first, the three leading State health commercialisation agencies from Queensland, New South Wales and the Australian Capital Territory recently signed a Memorandum of Understanding (MoU) to establish greater cooperation and information sharing.

Participating in the Alliance from Queensland is the Australian Institute for Commercialisation (AIC), from New South Wales, BioMed North Limited (BMN), and from the ACT, the National Health Sciences Centre Limited (NHSC).

It will encourage collaboration and knowledge sharing with a health innovation agenda. It will also leverage collective IP management and commercialisation skills and expertise, innovative R&D programs to increase value for government/s, research sectors, and industry alike.

The Alliance recognises that public hospitals and health services generate significant intellectual assets which, if properly managed, could be leveraged to provide increased public value, opportunities for collaborations that stimulate innovation, and lead to improved patient outcomes. It can also provide a mechanism to assist with responding to business drivers in health, including:

- Improved quality of patient care through innovative practices and technology, as well as sustainable support systems into the future;
- Improving research profile and reputation in health delivery practice innovation to attract top researchers and clinicians; and
- Reducing health service delivery costs, and enabling effective risk management at a hospital site level.

The signed MoU was an outcome of the recent 2nd Annual IP Management and Commercialisation for Hospitals Conference hosted by BioMed North at Westmead Hospital, Sydney in September 2008.

Contributions to the Office of Commercialisation NSCCAHS Newsletter - We are happy to publish your contributions, articles, press releases or calls for collaboration. Email the Publisher Ms Lindy Ferris lferris@officeofcommercialisation.com or call 0401 056 555.
